{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:46:53Z","timestamp":1790185613510,"version":"4.1.0"},"reference-count":37,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2018,4,1]]},"DOI":"10.1188\/18.cjon.175-183","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T17:06:56Z","timestamp":1521220016000},"page":"175-183","source":"Crossref","is-referenced-by-count":38,"title":["Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy"],"prefix":"10.1188","volume":"22","author":[{"given":"Elizabeth","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"1","unstructured":"Al Bahrani, B.J., Moylan, E.J., Forouzesh, B., Della-Fiorentina, S.A., & Goldrick, A.J. (2009). A short outpatient hydration schedule for cisplatin administration. Gulf Journal of Oncology, 5, 30\u201336."},{"key":"2","unstructured":"Al-Sarraf, M., Fletcher, W., Oishi, N., Pugh, R., Hewlett, J.S., Balducci, L., . . . Padilla, F. (1982). Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treatment Reports, 66, 31\u201335."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bellomo, R., Kellum, J.A., & Ronco, C. (2007). Defining and classifying acute renal failure: From advocacy to consensus and validation of the RIFLE criteria. Intensive Care Medicine, 33, 409\u2013413. https:\/\/doi.org\/10.1007\/s00134-006-0478-x","DOI":"10.1007\/s00134-006-0478-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bodnar, L., Wcislo, G., Gasowska-Bodnar, A., Synowiec, A., Szarlej-Wcis\u0142o, K., & Szczylik, C. (2008). Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. European Journal of Cancer, 44, 2608\u20132614.","DOI":"10.1016\/j.ejca.2008.08.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Dumas, M., de Gislain, C., d\u2019Athis, P., Chadoint-Noudeau, V., Escousse, A., Guerrin, J., & Autissier, N. (1989). Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Cancer Chemotherapy and Pharmacology, 23, 37\u201340. https:\/\/doi.org\/10.1007\/BF00258455","DOI":"10.1007\/BF00258455"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Guyatt, G., Oxman, A.D., Akl, E.A., Kunz, R., Vist, G., Brozek, J., . . . Sch\u00fcnemann, H.J. (2011). GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology, 64, 383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Horinouchi, H., Kubota, K., Itani, H., Taniyama, T.K., Nakamichi, S., Wakui, H., . . . Tamura, I.S.T. (2013). Short hydration in chemotherapy containing cisplatin (\u2265 75 mg\/m2) for patients with lung cancer: A prospective study. Japanese Journal of Clinical Oncology, 43, 1105\u20131109.","DOI":"10.1093\/jjco\/hyt122"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hotta, K., Takigawa, N., Hisamoto-Sato, A., Ichihara, E., Kudo, K., Uchida, K., . . . Kiura, K. (2013). Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Japanese Journal of Clinical Oncology, 43, 1115\u20131123.","DOI":"10.1093\/jjco\/hyt128"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Jones, D.P., Spunt, S.L., Green, D., & Springate, J.E. (2008). Renal late effects in patients treated for cancer in childhood: A report from the Children\u2019s Oncology Group. Pediatric Blood and Cancer, 51, 724\u2013731. https:\/\/doi.org\/10.1002\/pbc.21695","DOI":"10.1002\/pbc.21695"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., . . . Nakagawa, K. (2014). Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLOS ONE, 9(7), e101902. https:\/\/doi.org\/10.1371\/journal.pone.0101902","DOI":"10.1371\/journal.pone.0101902"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Launay-Vacher, V., Rey, J.-B., Isnard-Bagnis, C., Deray, G., & Daouphars, M. (2008). Prevention of cisplatin nephrotoxicity: State of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemotherapy and Pharmacology, 61, 903\u2013909. https:\/\/doi.org\/10.1007\/s00280-008-0711-0","DOI":"10.1007\/s00280-008-0711-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lavol\u00e9, A., Danel, S., Baudrin, L., Gounant, V., Ruppert, A.M., Epaud, C., . . . Milleron, B. (2012). Routine administration of a single dose of cisplatin \u2265 75 mg\/m2 after short hydration in an outpatient lung-cancer clinic. Bulletin du Cancer, 99, E43\u2013E48.","DOI":"10.1684\/bdc.2012.1555"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Leu, L., & Baribeault, D. (2010). A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. Journal of Oncology Pharmacy Practice, 16, 167\u2013171. https:\/\/doi.org\/10.1177\/1078155209346071","DOI":"10.1177\/1078155209346071"},{"key":"14","doi-asserted-by":"crossref","unstructured":"McKibbin, T., Cheng, L.L., Kim, S., Steuer, C.E., Owonikoko, T.K., Khuri, F.R., . . . Saba, N.F. (2016). Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Supportive Care in Cancer, 24, 1789\u20131793. https:\/\/doi.org\/10.1007\/s00520-015-2978-0","DOI":"10.1007\/s00520-015-2978-0"},{"key":"15","unstructured":"Melnyk, B.M., & Fineout-Overholt, E. (2015). Evidence-based practice in nursing and healthcare: A guide to best practice (3rd ed.). Philadelphia, PA: Lippincott Williams and Wilkins."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Miller, R.P., Tadagavadi, R.K., Ramesh, G., & Reeves, W.B. (2010). Mechanisms of cisplatin nephrotoxicity. Toxins, 2, 2490\u20132518. https:\/\/doi.org\/10.3390\/toxins2112490","DOI":"10.3390\/toxins2112490"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Morgan, K.P., Snavely, A.C., Wind, L.S., Buie, L.W., Grilley-Olson, J., Walko, C.M., & Weiss, J. (2014). Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Annals of Pharmacotherapy, 48, 863\u2013869. https:\/\/doi.org\/10.1177\/1060028014533303","DOI":"10.1177\/1060028014533303"},{"key":"18","unstructured":"Muraki, K., Koyama, R., Honma, Y., Yagishita, S., Shukuya, T., Ohashi, R., . . . Takahashi, K. (2012). Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. Journal of Thoracic Disease, 4, 562\u2013568. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2012.10.16"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Murray, A.W., Barnfield, M.C., Waller, M.L., Telford, T., & Peters, A.M. (2013). Assessment of glomerular filtration rate measurement with plasma sampling: A technical review. Journal of Nuclear Medicine Technology, 41, 67\u201375. https:\/\/doi.org\/10.2967\/jnmt.113.121004","DOI":"10.2967\/jnmt.113.121004"},{"key":"20","unstructured":"National Cancer Institute. (2010). Common terminology criteria for adverse events [v.4.03]. Retrieved from http:\/\/bit.ly\/2o2Zd4Y"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Oka, T., Kimura, T., Suzumura, T., Yoshimoto, N., Nakai, T., Yamamoto, N., . . . Hirata, K. (2014). Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: A toxicity study. BMC Pharmacology and Toxicology, 15, 70. https:\/\/doi.org\/10.1186\/2050-6511-15-70","DOI":"10.1186\/2050-6511-15-70"},{"key":"22","unstructured":"Ostrow, S., Egorin, M.J., Hahn, D., Markus, S., Aisner, J., Chang, P., . . . Wiernik, P.H. (1981). High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treatment Reports, 65, 73\u201378."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Ouchi, A., Asano, M., Aono, K., Watanabe, T., & Kato, T. (2014). Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose cisplatin. Journal of Oncology, 2014, 767652. https:\/\/doi.org\/10.1155\/2014\/767652","DOI":"10.1155\/2014\/767652"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Platania, M., Verzoni, E., & Vitali, M. (2015). Hyponatremia in cancer patients. Tumori, 101, 246\u2013248. https:\/\/doi.org\/10.5301\/tj.5000257","DOI":"10.5301\/tj.5000257"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Ruggiero, A., Rizzo, D., Trombatore, G., Maurizi, P., & Riccardi, R. (2016). The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: Real or not? Cancer Chemotherapy and Pharmacology, 77, 19\u201326. https:\/\/doi.org\/10.1007\/s00280-015-2913-6","DOI":"10.1007\/s00280-015-2913-6"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Sakaida, E., Iwasawa, S., Kurimoto, R., Ebata, T., Imai, C., Oku, T., . . . Takiguchi, Y. (2016). Safety of a short hydration method for cisplatin administration in comparison with a conventional method\u2014A retrospective study. Japanese Journal of Clinical Oncology, 46, 370\u2013377. https:\/\/doi.org\/10.1093\/jjco\/hyv203","DOI":"10.1093\/jjco\/hyv203"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Santoso, J.T., Lucci, J.A., 3rd, Coleman, R.L., Schafer, I., & Hannigan, E.V. (2003). Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemotherapy and Pharmacology, 52, 13\u201318. https:\/\/doi.org\/10.1007\/s00280-003-0620-1","DOI":"10.1007\/s00280-003-0620-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Skinner, R. (2011). Nephrotoxicity\u2014What do we know and what don\u2019t we know? Journal of Pediatric Hematology\/Oncology, 33, 128\u2013134. https:\/\/doi.org\/10.1097\/MPH.0b013e3181f8cac0","DOI":"10.1097\/MPH.0b013e3181f8cac0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Skinner, R., Parry, A., Price, L., Cole, M., Craft, A.W., & Pearson, A.D.J. (2009). Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors. European Journal of Cancer, 45, 3213\u20133219. https:\/\/doi.org\/10.1016\/j.ejca.2009.06.032","DOI":"10.1016\/j.ejca.2009.06.032"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Stevens, L.A., Coresh, J., Greene, T., & Levey, A.S. (2006). Assessing kidney function\u2014Measured and estimated glomerular filtration rate. New England Journal of Medicine, 354, 2473\u20132483. https:\/\/doi.org\/10.1056\/NEJMra054415","DOI":"10.1056\/NEJMra054415"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Tiseo, M., Martelli, O., Mancuso, A., Sormani, M.P., Bruzzi, P., Di Salvia, R., . . . Ardizzoni, A. (2007). Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori, 93, 138\u2013144.","DOI":"10.1177\/030089160709300205"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Vogl, S.E., Zaravinos, T., Kaplan, B.H., & Wollner, D. (1981). Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II). European Journal of Cancer, 17, 345\u2013350.","DOI":"10.1016\/0014-2964(81)90126-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Willox, J.C., McAllister, E.J., Sangster, G., & Kaye, S.B. (1986). Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial. British Journal of Cancer, 54, 19\u201323.","DOI":"10.1038\/bjc.1986.147"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Womer, R.B., Pritchard, J., & Barratt, T.M. (1985). Renal toxicity of cisplatin in children. Journal of Pediatrics, 106, 659\u2013663.","DOI":"10.1016\/S0022-3476(85)80098-6"},{"key":"35","unstructured":"Yamamoto, Y., Watanabe, K., Tsukiyama, I., Matsushita, H., Yabushita, H., Matsuura, K., & Wakatsuki, A. (2015). Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin. Anticancer Research, 35, 2199\u20132204."},{"key":"36","doi-asserted-by":"crossref","unstructured":"Yoshida, T., Niho, S., Toda, M., Goto, K., Yoh, K., Umemura, S., . . . Ohe, Y. (2014). Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: A retrospective study. Japanese Journal of Clinical Oncology, 44, 346\u2013354. https:\/\/doi.org\/10.1093\/jjco\/hyu004","DOI":"10.1093\/jjco\/hyu004"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zareifar, S., Jafari, H., Geramizadeh, B., Basiratnia, M., Golafshan, H., Cohan, N., . . . Hamidi, R. (2013). The evaluation of cisplatin effect on tubular function in children on chemotherapy. Pediatric Hematology and Oncology, 30, 18\u201324. https:\/\/doi.org\/10.3109\/08880018.2012.737093","DOI":"10.3109\/08880018.2012.737093"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/22\/2\/nephrotoxicity-evidence-patients-receiving-cisplatin-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T11:02:40Z","timestamp":1603969360000},"score":1,"resource":{"primary":{"URL":"http:\/\/cjon.ons.org\/cjon\/22\/2\/nephrotoxicity-evidence-patients-receiving-cisplatin-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1188\/18.cjon.175-183","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}